作为铁死诱导剂的黄素衍生物:设计,合成和抗乳腺癌活性评估
Nan Wu1, Yue Zhang1, Xiongjie Yin1
1Key Laboratory of Natural Medicines of the Changbai Mountain, Ministry of Education, Yanbian University College of Pharmacy, Yanji 133002, PR China.
Bioorganic & medicinal chemistry
|September 4, 2025
概括
库尔库明衍生物A4通过诱导铁和亡来对抗乳腺癌. 这种新型化合物针对关键途径, 提供新的癌症治疗和克服抗药性.
科学领域:
- 医学化学
- 癌症生物学
- 药理学
背景情况:
- 黄素 (CUR) 通过诱导亡和抑制增殖而表现出抗瘤特性.
- 像CUR这样的天然产品在癌症治疗方面受到广泛研究.
- 开发新的CUR衍生物可以提高抗癌效果.
研究的目的:
- 设计和合成具有增强抗癌活性的新型黄素衍生物.
- 调查最强大的衍生品A4的作用机制.
- 探索A4作为乳腺癌诱导剂的潜力.
主要方法:
- 合成包含1,2,3-三和异环的20种黄素衍生物.
- 使用4T1和MDA-MB-231细胞系进行体外抗繁殖和亡测定.
- 对包括反应性氧物种 (ROS),铁离子 (Fe2+),脂质过氧化 (LPO) 和谷氨 (GSH) 在内的铁化标志物的分析.
- 线粒体膜完整性和关键蛋白质表达的评估 (GPX4,SLC7A11,p53).
- 基因淘汰研究证实了信号通路.
主要成果:
- 化合物A4在体外对4T1和MDA- MB-231细胞具有显著的抗增殖活性.
- 在4T1细胞中诱导了剂量依赖的早期和晚期亡.
- 通过调节ROS,Fe2+,LPO和GSH水平,A4被确定为4T1细胞中的铁灭诱导剂.
- A4 破坏了线粒体膜的完整性和平衡.
- A4抑制了GPX4和SLC7A11的表达,同时促进了p53蛋白的表达.
- 基因淘汰确认A4通过p53/SLC7A11/GPX4途径诱导铁.
结论:
- 黄素衍生物A4是一种具有显著抗乳腺癌活性的新型铁亡诱导剂.
- A4通过亡和铁亡的结合诱导细胞死亡.
- 该p53/SLC7A11/GPX4途径涉及到A4介导的铁死.
- 在癌症治疗和克服抗药性方面,
相关概念视频
02:59Cancer Prevention
6.3K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
Some...
6.3K
01:15Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
02:34Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
01:10Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
02:57Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K